Seres Therapeutics (MCRB) Accumulated Depreciation & Amortization: 2015-2025
Historic Accumulated Depreciation & Amortization for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $56.4 million.
- Seres Therapeutics' Accumulated Depreciation & Amortization rose 8.06% to $56.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.2 million, marking a year-over-year increase of 5.65%. This contributed to the annual value of $53.2 million for FY2024, which is 8.39% up from last year.
- Seres Therapeutics' Accumulated Depreciation & Amortization amounted to $56.4 million in Q3 2025, which was up 1.89% from $55.3 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $56.4 million in Q3 2025 and a low of $35.8 million during Q1 2021.
- In the last 3 years, Seres Therapeutics' Accumulated Depreciation & Amortization had a median value of $52.4 million in 2024 and averaged $51.9 million.
- Data for Seres Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY grew of 21.17% (in 2021) over the last 5 years.
- Quarterly analysis of 5 years shows Seres Therapeutics' Accumulated Depreciation & Amortization stood at $40.3 million in 2021, then grew by 11.85% to $45.0 million in 2022, then climbed by 8.97% to $49.1 million in 2023, then increased by 8.39% to $53.2 million in 2024, then climbed by 8.06% to $56.4 million in 2025.
- Its last three reported values are $56.4 million in Q3 2025, $55.3 million for Q2 2025, and $54.3 million during Q1 2025.